Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140019/S013

i-FACTOR Peptide Enhanced Graft Substitute

Cerapedics, LLC · Decision date Apr 7, 2026

FDA DECISIONP140019/S013

What did the FDA decide?

FDA records P140019/S013 as a supplement to PMA P140019, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 7, 2026.

FDA approval order statement

Change in the location for performance of the mass spectral analysis for the P-15 drug substance release specification from SGS North America (NAM), Inc, West Chester PA as a contract laboratory to Bachem Americas to being performed inhouse at Bachem Americas, Torrence, CA
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Apr 7, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P140019/S013
Regulatory pathway
PMA supplement
Product code
NOX
Decision code
OK30
Decision date
Apr 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Filler, bone void, synthetic peptide.

Product code
NOX
FDA device class
3

For the original device and its historical approval scope, see PMA P140019. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P140019 · Original PMA

    I-FACTOR PEPTIDE ENHANCED BONE GRAFT

  2. P140019/S013 received

    Application receipt date recorded by FDA.

  3. P140019/S013 · FDA decision

    30-Day Notice

  4. P140019/S014 · Related supplement

    i-F ACTOR Peptide Enhanced Graft Substitute

Timeline entries are records held by MedtechLedger for P140019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140019

Product / regulatory recordCompanyPathwayDecision dateSource
Cerapedics, LLCPMA approvalNov 3, 2015FDA
Cerapedics, LLCPMA supplementSep 16, 2026FDA

Explore the linked device profile

Other records with product code NOX

Product / regulatory recordCompanyPathwayDecision dateSource
Cerapedics, Inc.PMA supplementSep 16, 2026FDA
Cerapedics, Inc.PMA supplementApr 7, 2026FDA
Cerapedics, Inc.PMA supplementDec 11, 2025FDA
Cerapedics, Inc.PMA approvalJun 18, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cerapedics, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
11025 Dover St., Suite 1600, Westminster, CO, 80021

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records